This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Attractive Dividend Growth Stocks on Sale
by Sweta Killa
Here are some attractive stock picks that are the major source of consistent income for investors when returns from the equity market are at risk.
The Zacks Analyst Blog Highlights: McDonald's, Thermo Fisher, Caterpillar, CSX and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: McDonald's, Thermo Fisher, Caterpillar, CSX and Celgene
Top Research Reports for McDonald's, Thermo Fisher & Caterpillar
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), Thermo Fisher (TMO) and Caterpillar (CAT).
Thermo Fisher (TMO) Beats on Q3 Earnings, Ups '18 Guidance
by Zacks Equity Research
Thermo Fisher (TMO) raises its 2018 revenue view, banking on a solid third-quarter operational performance, partially offset by a less favorable foreign exchange.
Thermo Fisher Scientific (TMO) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 2.75% and 3.93%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Q3 Earnings on Oct 24: BSX, ALGN & More
by Zacks Equity Research
Long-term potential of the Medical Products industry appears promising at the moment amid certain short-term geopolitical insecurities.
Is a Surprise Coming for Thermo Fisher Scientific (TMO) This Earnings Season?
by Zacks Equity Research
Thermo Fisher Scientific (TMO) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
What's in Store for Zimmer Biomet (ZBH) This Earnings Season?
by Zacks Equity Research
Focusing on areas like quality correction, supply recovery and product introductions, Zimmer Biomet (ZBH) is expected to see robust top-line numbers at S.E.T. arm in Q3.
Can Overall Growth Drive Thermo Fisher (TMO) Q3 Earnings?
by Zacks Equity Research
Thermo Fisher's (TMO) steadily strong analytical instrument business flaunts higher global demand.
Pacific Biosciences Introduces Enhancements to Sequel System
by Zacks Equity Research
The latest enhancements in Pacific Biosciences??? (PACB) Sequel System represent strong improvement in terms of read length, throughput and accuracy in DNA sequencing.
Will Edwards' (EW) Steady Overall Growth Drive Q3 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q3.
Can Overall Growth Drive Align Technology (ALGN) Q3 Earnings?
by Zacks Equity Research
Align Technology (ALGN) likely to gain from strength in Invisalign space as well as Scanner and Service business in Q3.
Will 5 Elements Drive Quest Diagnostics (DGX) Q3 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) growing partnerships with health care leaders and strategic acquisitions are expected to boost top and bottom-line growth in Q3.
Thermo Fisher Scientific (TMO) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Solid Overall Growth Drive Illumina (ILMN) Q3 Earnings?
by Zacks Equity Research
Illumina (ILMN) is likely to gain from strong revenues at the Product, Service and other segments in Q3.
Why Thermo Fisher (TMO) Could Beat Earnings Estimates Again
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus
by Sweta Jaiswal
Rising incidence of infectious diseases and increasing acceptance of companion diagnostics are driving the molecular diagnostics market.
Thermo Fisher (TMO) Scales a 52-Week High: What's Driving It?
by Zacks Equity Research
Thermo Fisher (TMO) sees strength in all end markets, categorized either by customer type or geography.
The Zacks Analyst Blog Highlights: Chevron, Amgen, Thermo Fisher, Estee Lauder and Delta Air Lines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Amgen, Thermo Fisher, Estee Lauder and Delta Air Lines
Thermo Fisher (TMO) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Stock Reports for Chevron, Amgen & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Chevron (CVX), Amgen (AMGN), and Thermo Fisher (TMO).
Here's Why You Should Hold on to Roper (ROP) Stock for Now
by Zacks Equity Research
Roper (ROP) stands to gain from acquired assets, healthy segmental business and operations in various markets. However, rising costs and buyout-related integration risks remain issues.
Stock Market News For Sep 10, 2018
by Zacks Equity Research
Markets ended sharply lower on Friday after President Donald Trump said that the United States was ready to move ahead with tariffs.
Thermo Fisher to Acquire BD's Advanced Bioprocessing Unit
by Zacks Equity Research
BD's (BDX) Advanced Bioprocessing business generates revenues worth $100 million annually. The unit will be integrated in the Thermo Fisher's (TMO) Life Sciences Solutions Segment.
Thermo Fisher (TMO) Up 0.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.